Evidence map›Paper›PMID 30764767›Full record

ArticleBMC infectious diseases2019

Urea dilution of serum for reproducible anti-HSV1 IgG avidity index.

Jan Olsson, Jörgen Johansson, Emma Honkala, Bert Blomqvist, Eloise Kok, Bodil Weidung, Hugo Lövheim, Fredrik Elgh

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Jan OlssonDepartment of Clinical Microbiology, Virology, Umeå University, SE-901 85, Umeå, Sweden. jan.l.olsson@umu.se.ORCID http://orcid.org/0000-0001-9094-319X
Jörgen JohanssonDepartment of Clinical Microbiology, Virology, Umeå University, SE-901 85, Umeå, Sweden.
Emma HonkalaDepartment of Clinical Microbiology, Virology, Umeå University, SE-901 85, Umeå, Sweden.
Bert BlomqvistDepartment of Clinical Microbiology, Virology, Umeå University, SE-901 85, Umeå, Sweden.
Eloise KokTampere University Hospital, Tampere, Finland.
Bodil WeidungDepartment of Public Health and Caring Sciences, Geriatric Medicine, Uppsala University, Uppsala, Sweden.
Hugo LövheimDepartment of Community Medicine and Rehabilitation, Geriatric Medicine, Umeå University, Umeå, Sweden.
Fredrik ElghDepartment of Clinical Microbiology, Virology, Umeå University, SE-901 85, Umeå, Sweden.
Umeå University · SETampere University Hospital · FIUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHerpes simplex virus type 1 (HSV1), establishes life-long latency and can cause symptoms during both first-time infection and later reactivation. The aim of the present study was to describe a protocol to generate a reliable and discriminative avidity index (AI) for anti-HSV1 IgG content in human sera.

methodsHuman serum from two distinct cohorts; one a biobank collection (Betula) (n = 28), and one from a clinical diagnostics laboratory at Northern Sweden University Hospital (NUS) (n = 18), were assessed for presence of IgG antibodies against HSV1 by a commercially available ELISA-kit. Addition of urea at the incubation step reduces effective binding, and the ratio between urea treated sample and non-treated sample was used to express an avidity index (AI) for individual samples.

resultsAI score ranged between 43.2 and 73.4% among anti-HSV1 positive biobank sera. Clinical samples ranged between 36.3 and 74.9%. Reproducibility expressed as an intraclass correlation coefficient (ICC) was estimated at 0.948 (95% CI: 0.900-0.979) and 0.989 (95% CI 0.969-0.996) in the biobank and clinical samples, respectively.

conclusionThe method allows for AI scoring of anti-HSV1 IgG from individual human sera with a single measurement. The least significant change between two measurements at the p < 0.05 level was estimated at 5.4 and 3.2 points, respectively, for the two assessed cohorts.

Indexed as

AdultAgedAged, 80 and overAntibodies, ViralAntibody AffinityEnzyme-Linked Immunosorbent AssayFemaleHerpesvirus 1, HumanHumansImmunoglobulin GImmunoglobulin MIndicator Dilution TechniquesMaleMiddle AgedReagent Kits, DiagnosticReproducibility of ResultsAntibodies, ViralImmunoglobulin GImmunoglobulin MReagent Kits, DiagnosticUreaAvidityELISAHerpes simplexIgGPrimary infectionReactivated infection

Identifiers

PMID30764767
PMCPMC6376645
OpenAlexW2924559829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.